Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;48(2):242-245.
doi: 10.1007/s00134-021-06601-0. Epub 2021 Dec 18.

The AKI care bundle: all bundle components are created equal-are they?

Thilo C von Groote  1 , Marlies Ostermann  2 , Lui G Forni  3   4 , Melanie Meersch-Dini  1 , Alexander Zarbock  5 ; PrevAKI Investigators
Collaborators, Affiliations

The AKI care bundle: all bundle components are created equal-are they?

Thilo C von Groote et al. Intensive Care Med. 2022 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

TCVG and MO declared no conflict of interest. AZ reported receiving research grants from Baxter, Fresenius, Astute Medical, and Astellas and receiving personal fees from Fresenius, AM Pharma and Biomerieux. MM reported receiving personal fees from Astute Medical, FMC, and Baxter. LGF declared research support and personal fees from Astute Medical, La Jolla Pharmaceuticals, Medibeacon, Baxter, and Fresenius.

Figures

Fig. 1
Fig. 1
a Univariate, binary logistic regression analysis for development of any AKI. ACEi angiotensin-converting enzyme inhibitors, ARBs angiotensin receptor blockers, OR odds ratio, MAP median arterial pressure, CI cardiac index. Hypotension: MAP < 60 mmHg on one reading or MAP < 65 mmHg on two readings during the intervention period. Hyperglycemia defined as: blood glucose levels ≥ 150 mg/dl longer than three hours during intervention period. b Hemodynamic status and AKI incidence. (gray = high MAP and/or CI; red = low MAP and/or CI). c Treatment effects of hemodynamic optimization for AKI prevention
See this image and copyright information in PMC

References

    1. Meersch M, Schmidt C, Hoffmeier A, Van Aken H, Wempe C, Gerss J, Zarbock A. Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial. Intensive Care Med. 2017;43(11):1551–1561. doi: 10.1007/s00134-016-4670-3. - DOI - PMC - PubMed
    1. Zarbock A, Küllmar M, Ostermann M, Lucchese G, Baig K, Cennamo A, Rajani R, McCorkell S, Arndt C, Wulf H, Irqsusi M, Monaco F, Di Prima AL, García Alvarez M, Italiano S, Miralles Bagan J, Kunst G, Nair S, L'Acqua C, Hoste E, et al. Prevention of cardiac surgery-associated acute kidney injury by implementing the KDIGO guidelines in high-risk patients identified by biomarkers: the PrevAKI-multicenter randomized controlled trial. Anesth Analg. 2021;133(2):292–302. doi: 10.1213/ANE.0000000000005458. - DOI - PubMed
    1. Göcze I, Jauch D, Götz M, Kennedy P, Jung B, Zeman F, Gnewuch C, Graf BM, Gnann W, Banas B, Bein T, Schlitt HJ, Bergler T. Biomarker-guided intervention to prevent acute kidney injury after major surgery: the prospective randomized BigpAK study. Ann Surg. 2018;267(6):1013–1020. doi: 10.1097/SLA.0000000000002485. - DOI - PubMed
    1. Joannidis M, Druml W, Forni LG, Groeneveld A, Honore PM, Hoste E, Ostermann M, Oudemans-van Straaten HM, Schetz M. Prevention of acute kidney injury and protection of renal function in the intensive care unit: update 2017: expert opinion of the Working Group on Prevention, AKI section, European Society of Intensive Care Medicine. Intensive Care Med. 2017;43(6):730–749. doi: 10.1007/s00134-017-4832-y. - DOI - PMC - PubMed
    1. Pickkers P, Ostermann M, Joannidis M, Zarbock A, Hoste E, Bellomo R, Prowle J, Darmon M, Bonventre JV, Forni L, Bagshaw SM, Schetz M. The intensive care medicine agenda on acute kidney injury. Intensive Care Med. 2017;43(9):1198–1209. doi: 10.1007/s00134-017-4687-2. - DOI - PMC - PubMed

LinkOut - more resources